Table III.
Evaluation of antibodies for ten TAAs selected in the detection of breast cancer.
| Positive % (No.)
|
|||||||
|---|---|---|---|---|---|---|---|
| Panel of TAAs | BC (41) | NHS (82) | Sensitivity | Specificity | YI | PPV | NPV |
| c-myc | 22.0 (9/41)a | 0 (0/82) | 22.0 | 100.0 | 0.220 | 100.0 | 71.9 |
| c-myc+survivin | 34.1 (14/41)a | 1.2 (1/82) | 34.1 | 98.8 | 0.329 | 93.3 | 75.0 |
| c-myc+survivin+cyclin B1 | 39.0 (16/41)a | 2.4 (2/82) | 39.0 | 97.6 | 0.366 | 88.9 | 76.2 |
| c-myc+survivin+cyclin B1+cyclin D1 | 43.9 (18/41)a | 4.9 (4/82) | 43.9 | 95.1 | 0.390 | 81.8 | 77.2 |
| c-myc+survivin+cyclin B1+cyclin D1 +p62 | 48.8 (20/41)a | 6.1 (5/82) | 48.8 | 93.9 | 0.427 | 80.0 | 78.6 |
| c-myc+survivin+cyclin B1+cyclin D1 +p62+p53 | 51.2 (21/41)a | 8.5 (7/82) | 51.2 | 91.5 | 0.427 | 75.0 | 78.9 |
| c-myc+survivin+cyclin B1+cyclin D1 +p62+p53+p16 | 56.1 (23/41)a | 11.0 (9/82) | 56.1 | 89.0 | 0.451 | 71.9 | 80.2 |
| c-myc+survivin+cyclin B1+cyclin D1 +p62+p53+p16+CDK2 | 61.0 (25/41)a | 11.0 (9/82) | 61.0 | 89.0 | 0.500 | 73.5 | 82.0 |
| c-myc+survivin+cyclin B1+cyclin D1 +p62+p53+p16+CDK2+Imp1 | 61.0 (25/41)a | 13.4 (11/82) | 61.0 | 86.6 | 0.476 | 69.4 | 81.6 |
| c-myc+survivin+cyclin B1+cyclin D1 +p62+p53+p16+Imp1+CDK2+koc | 61.0 (25/41)a | 13.4 (11/82) | 61.0 | 86.6 | 0.476 | 69.4 | 81.6 |
P-values relative to NHS:
a
P<0.01. TAA, tumor-associated antigen; BC, breast cancer; NHS, normal human sera; YI, Youden’s index; PPV, positive predictive value; NPV, negative predictive value.